Publications by authors named "Sivan Abramovitch"
Proc Natl Acad Sci U S A
July 2010
Article Synopsis
- EGFR is a validated target for cancer therapies due to its role in tumor growth, with several monoclonal antibodies (mAbs) developed to inhibit it, leading to clinical approvals and trials.
- Combining noncompetitive mAbs targeting EGFR domain 3 can significantly reduce receptor levels (up to 80%) in various cell lines, with effectiveness linked to receptor density.
- The mechanism of this down-regulation involves recycling inhibition and does not activate EGFR, resulting in reduced cell migration and proliferation, which is important for designing effective EGFR-targeted treatments.
Cancer Res
September 2008
Article Synopsis
- Semaphorin-3B (sema3B) and semaphorin-3F (sema3F) act as tumor suppressors in lung cancer, with sema3F effectively repelling endothelial cells, inhibiting their growth and survival.
- Sema3B is often cleaved by pro-protein convertases, rendering it inactive, but a mutant version (sema3B-m) is more resistant to this cleavage and effectively repels endothelial cells and induces their apoptosis.
- The effectiveness of sema3B-m over native sema3B in repelling endothelial cells is facilitated through the neuropilin-1 receptor, indicating that increased activity of pro-protein convertases in tumor cells can help tumors
